Precision BioSciences Management

Management criteria checks 3/4

Precision BioSciences' CEO is Michael Amoroso, appointed in Oct 2021, has a tenure of 3.08 years. total yearly compensation is $2.04M, comprised of 30.9% salary and 69.1% bonuses, including company stock and options. directly owns 0.39% of the company’s shares, worth $196.71K. The average tenure of the management team and the board of directors is 2.8 years and 4.1 years respectively.

Key information

Michael Amoroso

Chief executive officer

US$2.0m

Total compensation

CEO salary percentage	30.9%
CEO tenure	3.1yrs
CEO ownership	0.4%
Management average tenure	2.8yrs
Board average tenure	4.1yrs

Recent management updates

Recent updates

Analysts Just Made A Meaningful Upgrade To Their Precision BioSciences, Inc. (NASDAQ:DTIL) Forecasts

Aug 06

It's Down 29% But Precision BioSciences, Inc. (NASDAQ:DTIL) Could Be Riskier Than It Looks

Jun 23

Is Precision BioSciences (NASDAQ:DTIL) Using Debt In A Risky Way?

Mar 14

Is Precision BioSciences (NASDAQ:DTIL) Weighed On By Its Debt Load?

Dec 08

Precision BioSciences appoints chief business officer from within ranks, rejigs co-founders' roles

Sep 02

Despite Lacking Profits Precision BioSciences (NASDAQ:DTIL) Seems To Be On Top Of Its Debt

Apr 19

Analyst Forecasts Just Became More Bearish On Precision BioSciences, Inc. (NASDAQ:DTIL)

Mar 21

Precision BioSciences (NASDAQ:DTIL) Is Using Debt Safely

Dec 31

Precision BioSciences: Uniquely Positioned

Oct 07

CEO Compensation Analysis

How has Michael Amoroso's remuneration changed compared to Precision BioSciences's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2024	n/a	n/a	US$11m
Jun 30 2024	n/a	n/a	US$16m
Mar 31 2024	n/a	n/a	-US$20m
Dec 31 2023	US$2m	US$630k	-US$43m
Sep 30 2023	n/a	n/a	-US$49m
Jun 30 2023	n/a	n/a	-US$31m
Mar 31 2023	n/a	n/a	-US$59m
Dec 31 2022	US$4m	US$604k	-US$73m
Sep 30 2022	n/a	n/a	-US$76m
Jun 30 2022	n/a	n/a	-US$93m
Mar 31 2022	n/a	n/a	-US$40m
Dec 31 2021	US$6m	US$127k	-US$31m

Compensation vs Market: Michael's total compensation ($USD2.04M) is above average for companies of similar size in the US market ($USD652.28K).

Compensation vs Earnings: Michael's compensation has been consistent with company performance over the past year.

CEO

Michael Amoroso (46 yo)

3.1yrs

Tenure

US$2,039,281

Compensation

Mr. Michael Amoroso is Chairman of Abeona Therapeutics LLC. Mr. Amoroso serves as Director, President and Chief Executive Officer of Precision BioSciences, Inc. since October 15, 2021. He serves as Directo...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Michael Amoroso	President	3.1yrs	US$2.04m	0.39% $ 196.7k
John Kelly	CFO & Principal Accounting Officer	3.8yrs	US$1.08m	0.48% $ 241.8k
Jefferson Smith	Co-Founder & Chief Research Officer	no data	no data	1.06% $ 527.2k
Naresh Tanna	Chief of Staff to CEO & Head of Investor Relations	less than a year	no data	no data
Dario Scimeca	General Counsel & Secretary	5.4yrs	US$1.51m	0.11% $ 54.9k
Bruce Stevens	Vice President of Quality & Compliance	4.8yrs	no data	no data
Maurissa Messier	Senior Director of Corporate Communications	no data	no data	no data
Juli Blanche	Chief People Officer	2.5yrs	no data	no data
Garrett Gincley	Head of Manufacturing	no data	no data	no data
Cindy Atwell	Chief Business Officer	no data	no data	no data
Neil Leatherbury	Senior VP and Head of Chemistry	1.8yrs	no data	no data
Murray Abramson	Senior VP & Head of Clinical Development	less than a year	no data	no data

2.8yrs

Average Tenure

50yo

Average Age

Experienced Management: DTIL's management team is considered experienced (2.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Michael Amoroso	President	3.1yrs	US$2.04m	0.39% $ 196.7k
Kenneth Anderson	Member of Scientific Advisory Board	5.8yrs	no data	no data
Hagop M. Kantarjian	Member of Scientific Advisory Board	5.8yrs	no data	no data
Raymond Schinazi	Member of Scientific Advisory Board	5.8yrs	US$256.47k	no data
Kevin Buehler	Independent Lead Director	5yrs	US$188.49k	0.061% $ 30.3k
Alan List	Clinical Consultant & Member of Scientific Advisory Board	less than a year	US$909.97k	0.062% $ 30.9k
Geno Germano	Independent Director	4.7yrs	US$169.74k	0.058% $ 29.0k
Samuel Wadsworth	Independent Director	3yrs	US$149.99k	0.058% $ 29.0k
Shari Pire	Independent Director	3yrs	US$158.90k	0.058% $ 29.0k
Melinda Brown	Independent Director	2.5yrs	US$158.99k	0.058% $ 29.0k
Cameron Turtle	Member of Scientific Advisory Board	5.8yrs	no data	no data
Stanley Frankel	Independent Director	3.6yrs	US$156.24k	0.059% $ 29.3k

4.1yrs

Average Tenure

67yo

Average Age

Experienced Board: DTIL's board of directors are considered experienced (4.1 years average tenure).

Precision BioSciences Management

Management criteria checks 3/4

Key information

Recent management updates

Precision BioSciences, Inc Announces Executive Changes Changes

Precision BioSciences, Inc., Annual General Meeting, Jun 04, 2024

Precision BioSciences, Inc. Announces Management Changes

Co-Founder notifies of intention to sell stock

Less than half of directors are independent

Precision BioSciences, Inc. Announces Raymond Schinazi Resigns from Board and as Chair of Nominating and Corporate Governance Committee and Member of Compensation Committee and Science and Technology Committee

Recent updates

Precision BioSciences, Inc. to Report Q3, 2024 Results on Nov 04, 2024

Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B

Precision BioSciences, Inc Announces Executive Changes Changes

Precision BioSciences, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Precision Biosciences, Inc. Presents New Preclinical Safety Data for Pbgene-Hbv Clinical Candidate At the European Association for the Study of the Liver Congress

Precision BioSciences, Inc. to Report Q1, 2024 Results on May 13, 2024

Precision BioSciences, Inc., Annual General Meeting, Jun 04, 2024

Precision BioSciences, Inc. to Report Q4, 2023 Results on Mar 27, 2024

Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency

Precision BioSciences, Inc. has filed a Follow-on Equity Offering.

Precision BioSciences, Inc. Receives Pre-IND Feedback from US FDA for PBGENE-HBV as It Advances Towards Clinical Readiness

Precision BioSciences, Inc. announced that it expects to receive funding from TG Therapeutics, Inc.

Precision Biosciences Announces Approval of First Clinical Trial Application of Arcus Gene Insertion Program by Partner iEcure

Precision BioSciences, Inc. Announces Publication in Nature Metabolism Supporting ARCUS In Vivo Gene Editing as a Potentially Curative Treatment for Mitochondrial Diseases

Precision BioSciences, Inc. Presents Late-Breaking Data Highlighting Preclinical Efficacy and Safety of PBGENE-HBV for Chronic Hepatitis B at AASLD’s The Liver Meeting 2023

Precision BioSciences, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Precision BioSciences Receives Approval from The Nasdaq Stock Market LLC to Transfer the Listing of its Common Stock from the Nasdaq Global Select Market to the Nasdaq Capital Market

Precision BioSciences Receives Approval from The Nasdaq Stock Market LLC to Transfer the Listing of its Common Stock from the Nasdaq Global Select Market to the Nasdaq Capital Market

Price target decreased by 15% to US$2.60

Precision BioSciences, Inc. Announces Management Changes

Consensus revenue estimates increase by 47%

Analysts Just Made A Meaningful Upgrade To Their Precision BioSciences, Inc. (NASDAQ:DTIL) Forecasts

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Precision BioSciences, Inc. to Report Q2, 2023 Results on Aug 04, 2023

Price target decreased by 24% to US$5.07

Precision Biosciences, Inc. Provides Updates on Azer-Cel FDA Meeting, Potential Partnerships and Timing of in Vivo R&D Day

It's Down 29% But Precision BioSciences, Inc. (NASDAQ:DTIL) Could Be Riskier Than It Looks

Precision Biosciences, Inc. Announces Oral Presentation of Positive Arcus Gene Editing Data At International Liver Congress 2023

Precision Biosciences, Inc. Presents Preclinical Data Demonstrating Potential of ARCUS for Treatment of Duchenne Muscular Dystrophy at American Society of Gene & Cell Therapy 26th Annual Meeting

Consensus revenue estimates increase by 17%, EPS downgraded

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates fall by 27%

Price target decreased by 11% to US$6.00

Is Precision BioSciences (NASDAQ:DTIL) Using Debt In A Risky Way?

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

Precision BioSciences Receives Favorable Type C Feedback from the FDA on the Company’s Chemistry, Manufacturing, and Controls (CMC) Strategies for Late-Stage Development of Azercabtagene Zapreleucel, Its Lead Allogeneic Car T Clinical Candidate

Precision BioSciences, Inc. Presents Analysis of Azer-Cel, Allogeneic CAR T Product Attributes Related to In Vivo Pharmacokinetics, Pharmacodynamics, and Clinical Outcomes at 2022 American Society of Hematology Annual Meeting

Is Precision BioSciences (NASDAQ:DTIL) Weighed On By Its Debt Load?

Co-Founder notifies of intention to sell stock

Consensus revenue estimates increase by 15%

Less than half of directors are independent

Price target decreased to US$6.63

Precision BioSciences, Inc. Announces Raymond Schinazi Resigns from Board and as Chair of Nominating and Corporate Governance Committee and Member of Compensation Committee and Science and Technology Committee

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Precision BioSciences, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Chief Financial Officer recently bought US$60k worth of stock

Precision BioSciences, Inc Announces Executive Promotions

Precision BioSciences appoints chief business officer from within ranks, rejigs co-founders' roles

Precision BioSciences: CAR T Data Updates End Of 2022 And Plenty Of Cash

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Precision BioSciences Q2 2022 Earnings Preview

Precision BioSciences, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Precision BioSciences, Inc. has completed a Follow-on Equity Offering in the amount of $50.000001 million.

Precision BioSciences, Inc.(NasdaqGS:DTIL) dropped from Russell 2000 Dynamic Index

Chief Financial Officer recently bought US$51k worth of stock

Consensus forecasts updated

Price target decreased to US$10.63

Precision BioSciences, Inc. Provides Update on Allogeneic CAR T Programs and Path Forward with Its Lead PBCAR0191 Candidate for CAR T Relapsed Patient Population

Precision Biosciences, Inc. Appoints Melinda Brown to its Board of Directors and Chair of the Board’s Audit Committee

Precision BioSciences, Inc. Appoints Juli Blanche as Chief People Officer

Consensus forecasts updated

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Precision Bio: Another CAR-T Laggard With No Solid Prospects

Precision BioSciences, Inc. to Report Q1, 2022 Results on May 09, 2022

Price target decreased to US$12.50

High number of new directors

Despite Lacking Profits Precision BioSciences (NASDAQ:DTIL) Seems To Be On Top Of Its Debt

Precision BioSciences, Inc. Announces Shalini Sharp Will Not Seek Re-Election to the Board of Directors